Physician profile
Kirk Jackson
NPI 1316977945
$4,376.71
in general payments reported to CMS, 2019-2025
28 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $247 · 2021: $348 · 2022: $643 · 2023: $712 · 2024: $699 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682 · Education: $67.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,681.92 |
| Education | $67.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $1,060.03 | 2021-2025 | Omnipod, Omnipod |
| Novo Nordisk INC | $892.23 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Si-Bone, INC. | $441.99 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $413.48 | 2022-2025 | Recorlev |
| Dexcom, INC. | $266.02 | 2021-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Lilly USA, LLC | $245.48 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $201.38 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $151.22 | 2019 | |
| Currax Pharmaceuticals LLC | $105.34 | 2020-2023 | Contrave, Nexletol, Onzetra Xsail |
| Corcept Therapeutics | $86.09 | 2024-2025 | Korlym |
| Avanir Pharmaceuticals, INC. | $49.17 | 2020-2022 | |
| Mannkind Corporation | $42.50 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $41.13 | 2020-2021 | |
| Pfizer INC. | $40.96 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.31 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $34.79 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Melinta Therapeutics, LLC | $34.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.90 | 2019 | |
| Halozyme INC | $31.40 | 2023 | |
| Merck Sharp & Dohme LLC | $30.10 | 2019-2020 | |
| Lundbeck LLC | $29.87 | 2023 | Rexulti |
| Eisai INC. | $23.68 | 2020-2021 | |
| Mylan Specialty L.P. | $18.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.53 | 2020 | |
| Astellas Pharma US INC | $13.82 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.76 | 2022 | |
| Glaxosmithkline, LLC. | $13.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.